Because of the scarcity of effective treatments, infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are widely recognized as a serious public health issue. As a result, researchers conducted this meta-analysis to assess the in vitro efficacy of recently licensed medicines against MRSA isolates based on previously published data. Investigators looked for papers that examined the in vitro activity of telavancin, dalbavancin, oritavancin, and tedizolid against MRSA isolates in electronic databases such as PubMed, Scopus, and Web of Science up until November 30, 2020. STATA software was used for the statistical analysis (version 14.0). In this meta-analysis, 38 studies were incorporated. Tedizolid had a total in vitro activity of 0.250 and 0.5 µg/mL for MIC50 and MIC90 (minimum inhibitory concentrations at which 50% and 90% of isolates were suppressed, respectively) on 12,204 MRSA isolates. Dalbavancin had a total antibacterial activity of 0.060 and 0.120 µg/mL for MIC50 and MIC90, respectively, against 28,539 MRSA isolates. Oritavancin’s total antibacterial activity against 420 MRSA isolates was 0.120 µg/mL for MIC50 and 0.045 µg/mL for MIC90, respectively. For MIC50 and MIC90, telavancin’s total antibacterial activity against 7,353 MRSA isolates was 0.032 and 0.060 µg/mL, respectively. Total susceptibility to tedizolid, telavancin, and dalbavancin was 100% (95% CI:100-100). Strong in vitro action against MRSA isolates was shown by telavancin, dalbavancin, oritavancin, and tedizolid. These drugs’ low MICs and high susceptibility rates provide a promising path for the introduction of future antibiotics that will be effective in treating MRSA infections.
Source: ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-022-00529-z
